Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis

NCT ID: NCT04360187

Last Updated: 2022-06-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

391 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-27

Study Completion Date

2021-09-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a phase 3, randomized, double blind and vehicle study to evaluate the efficacy and safety of Crisaborole ointment, 2% in Chinese and Japanese subjects with mild to moderate atopic dermatitis involving at least 5% treatable BSA. Eligible subjects will be randomized in a 2:1 ratio to one of 2 treatment groups (Crisaborole BID, Vehicle BID, respectively).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atopic Dermatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Crisaborole ointment

Crisaborole ointment application twice daily for 28 days

Group Type EXPERIMENTAL

Crisaborole Ointment

Intervention Type DRUG

Crisaborole ointment 2%

Crisaborole Placebo Vehicle

Vehicle Ointment application twice daily for 28 days

Group Type PLACEBO_COMPARATOR

Crisaborole Placebo Vehicle

Intervention Type DRUG

Placebo for crisaborole ointment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Crisaborole Ointment

Crisaborole ointment 2%

Intervention Type DRUG

Crisaborole Placebo Vehicle

Placebo for crisaborole ointment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Is male or female 2 years and older at the Screening visit/time of informed consent/assent diagnosed with mild-moderate AD (according to the criteria of Hanifin and Rajka), of at least 5% BSA.

Exclusion Criteria

* Has any clinically significant medical disorder, condition, or disease (including active or potentially recurrent non AD dermatological conditions and known genetic dermatological conditions that overlap with AD, such as Netherton syndrome) or clinically significant physical examination finding at Screening that in the PI's or designee's opinion may interfere with study objectives.
* Has participated in a previous crisaborole clinical study.
Minimum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Site Status

Dermatology Hospital of Southern Medical University

Guangzhou, Guangdong, China

Site Status

Guangzhou First People's Hospital

Guangzhou, Guangdong, China

Site Status

The Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

Site Status

The First Affiliated Hospital of Shantou University Medical College

Shantou, Guangdong, China

Site Status

Shenzhen Children's Hospital

Shenzhen, Guangdong, China

Site Status

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Site Status

The Second Xiangya Hospital of Central South University

Changsha, Hunan, China

Site Status

The First hospital of Jilin University

Changchun, Jilin, China

Site Status

Shandong Provincial Institute of Dermatology and Venereology & Shandong Provincial Hospital for Skin

Jinan, Shandong, China

Site Status

Huashan Hospital Fudan University

Shanghai, Shanghai Municipality, China

Site Status

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China

Site Status

First Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, China

Site Status

Hangzhou Third Hospital

Hangzhou, Zhejiang, China

Site Status

Zhejiang Provincial People's Hospital/Dermatology Department

Hangzhou, Zhejiang, China

Site Status

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

Site Status

The first Affiliated hospital of Wenzhou medical University

Wenzhou, Zhejiang, China

Site Status

Peking University People's Hospital

Beijing, , China

Site Status

Beijing Children's Hospital, Capital Medical University

Beijing, , China

Site Status

The Second Affiliated Hospital of Army Medical University,PLA

Chongqing, , China

Site Status

Children's Hospital of Shanghai

Shanghai, , China

Site Status

Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

Tianjin, , China

Site Status

Miyata Dermatology Clinic

Matsudo, Chiba, Japan

Site Status

Shirao Clinic of Pediatrics and Pediatric Allergy

Hiroshima, Hiroshima, Japan

Site Status

Motomachi Dermatology Clinic

Asahikawa-shi, Hokkaido, Japan

Site Status

Chitose dermatology and plastic surgery clinic

Chitose Shi, Hokkaido, Japan

Site Status

Takagi Dermatological Clinic

Obihiro, Hokkaido, Japan

Site Status

Yoshimura Child Clinic

Akashi, Hyōgo, Japan

Site Status

Iryouhoujinshadan Yamayurikai Tsujino. Kodomo Clinic

Kobe, Hyōgo, Japan

Site Status

Nomura Dermatology Clinic

Yokohama, Kanagawa, Japan

Site Status

Noguchi Dermatology Clinic

Kamimashiki-gun, Kumamoto, Japan

Site Status

Yoshioka Dermatology Clinic

Neyagawa, Osaka, Japan

Site Status

Kume Clinic

Sakai, Osaka, Japan

Site Status

Mildix Skin Clinic

Adachi-ku, Tokyo, Japan

Site Status

Yoga Allergy Clinic

Setagaya-ku, Tokyo, Japan

Site Status

Sugamo Kobayashi Derma Clinic

Toshima-Ku, Tokyo, Japan

Site Status

Sugamo Sengoku Dermatology

Toshima-Ku, Tokyo, Japan

Site Status

Hoshikuma Dermatology・Allergy Clinic

Fukuoka, , Japan

Site Status

Hallym University Kangnam Sacred Heart Hospital

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China Japan South Korea

References

Explore related publications, articles, or registry entries linked to this study.

Ma L, Tao X, Liu S, Cheng H, Fang R, Zhao Y, Cha A, Encinas GA, Zhou Y, Deng Y, Zhang J. Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged >/= 2 Years with Mild to Moderate Atopic Dermatitis. Dermatol Ther (Heidelb). 2024 May;14(5):1229-1243. doi: 10.1007/s13555-024-01156-6. Epub 2024 May 15.

Reference Type DERIVED
PMID: 38748345 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://pmiform.com/clinical-trial-info-request?StudyID=C3291032

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C3291032

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Steroid-reducing Effects of Crisaborole
NCT03832010 COMPLETED PHASE4